Galapagos NV and AbbVie recently expanded their collaborative agreement in cystic fibrosis (CF) to mirror the successful growth of their CF…
Articles by Daniela Semedo, PhD
The Cystic Fibrosis Foundation announced that it welcomes the recent creation of a Cystic Fibrosis Caucus in the U.S.
AmpliPhi Biosciences, a biotech company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, recently presented new…
TGV-Inhalonix announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to its antimicrobial agent as a possible treatment for antibiotic-resistant…
Raptor Pharmaceutical Corp. announced that the first commercial sales of Quinsair (levofloxacin inhalation solution), a treatment for adults with cystic fibrosis,…
Over 500 members and volunteers of the Cystic Fibrosis Foundation were present at the recent 2016 Volunteer Leadership Conference, a…
Early nutritional intervention and monitoring for respiratory and gastrointestinal disease in the youngest cystic fibrosis (CF) patients is vital to improving…
Personalized medicine, providing treatments tailored to individual factors down to the molecular level, is a promising approach for a highly variable disease…
Laurent Pharmaceuticals, Inc., recently announced the completion of a financing round, led by the Cystic Fibrosis Canada, to support a Phase 2…
The U.S. Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) designation to MP-376, Raptor Pharmaceutical’s inhaled levofloxacin to treat…